Crispr stock is down for the fifth straight week as the top Cathie Wood’s holding struggles amid dim expectations for its gene-editing drug.

The post Crispr Stock, A Cathie Wood Holding, Dives For The Fifth Straight Week — Here’s Why appeared first on Investor’s Business Daily.